At this year's EHA meeting, we spoke with leading experts about what was trending on Twitter and how you can make the most out of Twitter in your professional role.

Learn how to make the most out of Twitter in your professional role and stay up to date with what's trending at EHA 2021.

During this year's EHA meeting, VJSocial will be hosting a series of social media masterclasses to discuss trending topics across the spectrum of hematological malignancies and help hematologists, researchers, nurses, and allied medical professionals learn how to leverage the power of Twitter in their professional roles.

VJSocial

10–17 June 2021

Marco Herling of @UniLeipzig discusses the safety and efficacy of tagraxofusp for the treatment of BPDCN:

🎥: http://ow.ly/hq9y50JGpAF

@EHA_Hematology #EHA2022 #RareDiseases #BPDCN

📣 Our latest podcast is now live! Join UK experts Graham Jackson & Martin Kaiser as they discuss myeloma treatment in the UK, highlighting updates from Muk Nine b: OPTIMUM, the importance of chromosome 1q & more!

🎧: http://ow.ly/Rmji50JGF6U

#MMsm #HemOnc #Myeloma

Want to learn more about myeloma treatment in the UK?

Join experts Graham Jackson (@profghjackson) & Martin Kaiser in this exclusive session as they discuss:

- Muk Nine b: OPTIMUM
- Myeloma XI
- Genomics in myeloma

& more!

👉http://ow.ly/qqgH50JEOpX👈

#MMsm #HemOnc

📣 Our latest podcast is now live! Join UK experts Graham Jackson & Martin Kaiser as they discuss myeloma treatment in the UK, highlighting updates from Muk Nine b: OPTIMUM, the importance of chromosome 1q & more!

🎧: http://ow.ly/Rmji50JGF6U

#MMsm #HemOnc #Myeloma

On June 24, the @US_FDA approved lisocabtagene maraleucel (liso-cel) for second-line treatment of adult patients with LBCL. The efficacy of liso-cel has been evaluated in the TRANSFORM study.

Find out more here:

👉http://ow.ly/QqNu50JJj3z👈

#LymSM #HemOnc #CARTcell #ImmunoOnc

Load More...

VJSocial

10–17 June 2021

At this year's EHA meeting, we spoke with leading experts about what was trending on Twitter and how you can make the most out of Twitter in your professional role.

Learn how to make the most out of Twitter in your professional role and stay up to date with what's trending at EHA 2021.

During this year's EHA meeting, VJSocial will be hosting a series of social media masterclasses to discuss trending topics across the spectrum of hematological malignancies and help hematologists, researchers, nurses, and allied medical professionals learn how to leverage the power of Twitter in their professional roles.

View all videos

Marco Herling of @UniLeipzig discusses the safety and efficacy of tagraxofusp for the treatment of BPDCN:

🎥: http://ow.ly/hq9y50JGpAF

@EHA_Hematology #EHA2022 #RareDiseases #BPDCN

📣 Our latest podcast is now live! Join UK experts Graham Jackson & Martin Kaiser as they discuss myeloma treatment in the UK, highlighting updates from Muk Nine b: OPTIMUM, the importance of chromosome 1q & more!

🎧: http://ow.ly/Rmji50JGF6U

#MMsm #HemOnc #Myeloma

Want to learn more about myeloma treatment in the UK?

Join experts Graham Jackson (@profghjackson) & Martin Kaiser in this exclusive session as they discuss:

- Muk Nine b: OPTIMUM
- Myeloma XI
- Genomics in myeloma

& more!

👉http://ow.ly/qqgH50JEOpX👈

#MMsm #HemOnc

📣 Our latest podcast is now live! Join UK experts Graham Jackson & Martin Kaiser as they discuss myeloma treatment in the UK, highlighting updates from Muk Nine b: OPTIMUM, the importance of chromosome 1q & more!

🎧: http://ow.ly/Rmji50JGF6U

#MMsm #HemOnc #Myeloma

On June 24, the @US_FDA approved lisocabtagene maraleucel (liso-cel) for second-line treatment of adult patients with LBCL. The efficacy of liso-cel has been evaluated in the TRANSFORM study.

Find out more here:

👉http://ow.ly/QqNu50JJj3z👈

#LymSM #HemOnc #CARTcell #ImmunoOnc

Load More...

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter